Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Corporate Governance > Management

Management

Rajesh C. Shrotriya, MD
Chairman and Chief Executive Officer
Rajesh Shrotriya,

In September 2000, Dr. Shrotriya joined the Company as President and Chief Operating Officer and in August 2002, he was appointed Chief Executive Officer. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc.

Previously, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research.

Dr. Shrotriya is a 2011 Ernst & Young Orange County Region Entrepreneur of the Year® award winner. Dr. Shrotriya was specifically cited for his turn-around of Spectrum. The Ernst & Young LLP award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Dr. Shrotriya was chosen from 15 finalists by a panel of independent judges.


Joseph W. Turgeon
President and Chief Operating Officer
Joseph Turgeon

Mr.  Turgeon has global responsibility for leading Commercial Operations, Medical and Clinical Development and Pharmaceutical Operations.

Prior to joining the Company, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President, Sales where he built and led the sales organization across multiple areas, including oncology, inflammation and bone health.  Mr. Turgeon was responsible for launching most of the drugs and their dramatic growth at Amgen.  He brings depth of experience in the oncology marketplace.

Mr. Turgeon holds a B.S. from Jacksonville University where he studied microbiology and economics.


Kurt A. Gustafson
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Kurt Gustafson

Mr. Gustafson has more than 20 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations.

Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he managed several successful financings and established a three year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years most recently as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as CFO of Amgen International and resided in Zug, Switzerland.

Mr. Gustafson holds a Bachelors of Arts degree in Accounting from North Park University in Chicago and a Masters in Business Administration from University of California, Los Angeles.


Thomas J. Riga
Senior Vice President and Chief Commercial Officer
Thomas J. Riga

Mr. Riga is responsible for the commercialization and sales of all Spectrum products in US and globally.

Mr. Riga brings over 15 years of experience in the pharmaceutical and biotechnology industry.  His experience spans sales, marketing, manufacturing, and corporate accounts.  Throughout his career, Tom has delivered top tier results in a variety of functional areas within commercial.  

 

Pramod K. Gupta, PhD
Senior Vice President, Pharmaceutical Operations
Pramod Gupta,

Pramod Gupta is responsible for product development, and commercial manufacturing and supply chain, of Spectrum products. His product development responsibilities include chemical development, formulation development, analytical development, scale-up/manufacturing, stability studies, clinical supplies and intellectual property.  His supply chain responsibilities include commercial product inventory management, product manufacturing and shipment, and contracts management.

Pramod has over 25 years’ experience in the pharmaceutical industry including Abbott, Baxter and Bausch & Lomb, where he held positions of increasing responsibilities.  He has been part of over 12 approved NDAs and over 35 product launches globally.  Pramod holds PhD in Pharmaceutical Sciences, has published more than 50 papers and 2 scientific books, and holds over 12 granted patents.  He has also served as an expert committee member for the United States Pharmacopoeia.


Zane Yang, MD
Senior Vice President, Clinical Development
Zane Yang,
Dr. Yang joins Spectrum from Inovio Pharmaceuticals where he was Vice President, Clinical Development Oncology for Inovio's entire Oncology Therapeutic Area. He led Inovio's Clinical Development for all oncology immunotherapies and cancer vaccines, as well as all collaborative activities with external organizations.  Prior to Inovio, he was Director of Medical Affairs and Clinical Development at Janssen, Novartis Oncology and Merck & Co.
 
Dr. Yang, who earned his M.D. at Beijing Medical University, was a fellow at Emory University's Winship Cancer Institute, University of Pennsylvania and the Wistar Institute in Philadelphia. Before transitioning to the pharmaceutical industry, he was associate professor at the University of Virginia Medical Center in Charlottesville, VA.

Avi N. Oler, CFA
Vice President, Operations and Chief of Staff to the CEO
Lisa A. Croissant
Vice President, Sales
Bimal R. Shah
Vice President, Corporate and Business Development

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
6.54
Change:
- 0.16
Day High:
6.75
Day Low:
6.54
Volume:
360,989
3:18 PM ET on Mar 28, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR